Roth Capital on Nicotine in US and Benefits to 22nd Century Group (XXII), 'only FDA-approved minimum nicotine content cigarettes on the market'
Tweet Send to a Friend
Roth Capital analyst Brian Wright reiterated a Buy rating and $6.00 price target on 22nd Century Group (NASDAQ: XXII).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
